Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **MicroPort CardioFlow Medtech Corporation**

## 微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The board (the "Board") of directors (the "Directors") of MicroPort CardioFlow Medtech Corporation (the "Company", together with its subsidiaries the "Group") hereby announces that on June 22, 2022, the Company has resolved to grant share options (the "Options") to eligible participants (the "Grantees"), who are (i) director and employees of the Group and (ii) employees of MicroPort Scientific Corporation, to subscribe for up to an aggregate of 3,745,000 ordinary shares of the Company of US\$0.000005 each (the "Shares") in the capital of the Company pursuant to the share option scheme adopted by the Company on March 13, 2020 and amended on March 17, 2022, subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of Grant: June 22, 2022 (the "**Date of Grant**")

Exercise price of the Options HK\$2.802 per Share, representing the highest of (i) the granted: closing price of HK\$2.670 per Share as stated in the daily

quotations sheet issued by the The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on the Date of Grant; (ii) the average closing price of HK\$2.802 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of

US\$0.00005

Number of Options granted: 3,745,000 Options (each Option shall entitle the holder of

the Option to subscribe for one Share)

Validity period of the Options: Ten (10) years from the Date of Grant

Vesting period of the Options: The Options shall be vested in five (5) years, 20% of which

shall be vested on each anniversary of the Date of Grant

Among the Grantees, our executive Director, Mr. Zhao Liang, was granted 700,000 Options. The grant of Options to the executive Director has been approved by all the independent non-executive Directors of the Company pursuant to Rule 17.04(1) of the Listing Rules.

To the best knowledge and belief of the Board, save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, nor an associate (as defined under the Listing Rules) of any of them.

By order of the Board

MicroPort CardioFlow Medtech Corporation

Luo Qiyi

Chairman

Shanghai, PRC, June 22, 2022

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.